-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3118 Brazilian Non-Hodgkin T Cell Registry: An Exploratory Analysis of Extranodal SitesClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, real-world evidence
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Thais Fischer, MD1,2*, Eliana C M CM Miranda, PhD, MEd3*, Nelson Castro, MD4*, Juliana Pereira, MD, PhD5, Davimar Miranda Maciel Borducchi, PhD6, Samuel de S Medina, MD7*, Sergio Augusto B Brasil, MD, PhD8*, Danielle Leao Cordeiro De Farias, MD, MSc, MBA9, Marcelo Bellesso, MD10*, Jamila Vaz Tavarez, MD11*, Karin Z Cecyn, MD12*, Rony Schaffel, MD, PhD13, Samir Nabhan, MD14*, Frederico Lisboa Nogueira, MD15, Renata Baptista, MD16*, Fernando Barroso, MD17*, Renata R Souza, MD17*, Mateus Dalló Dal Pont, MD18*, Carolina Colaço Vilarim, MD19*, Claudio G Macedo, MD19*, Ademar Dantas Cunha, PhD20*, Patricia Giacon, MD21*, Elizete Negreiros, MD22*, Nelson Hamerschlak, MD, PhD23, Vera Figueiredo, MD24*, Diego Villa Cle, MD, MBA, PhD25*, Natalia Pin Chuen Zing, MD, MSc26,27*, Maria Almeida Dias, MD28*, Rafael Gaiolla, MD, PhD29*, Yung Bruno Gonzaga, MD30*, Joao Tadeu Damian Souto Filho, MD31*, Eduardo F O Ribeiro, MD32*, Gilnara Fontinele Silva, MD33*, Suellen Ka Gi Mo, MD34*, Guilherme F Perini, MD35*, Milena Matedi, MD36*, Abrahão Elias Hallack Neto, MD, PhD37*, Yana S Rabelo, MD38*, Massimo Federico, MD39, Carmino A Souza, MD40* and Carlos Chiattone, MD, PhD41,42*

1Santa Casa de São Paulo Medical School, São Paulo, Brazil
2AC Camargo Cancer Center, Sao Paulo, AC, Brazil
3University of Campinas, Campinas, Brazil
4Hospital de Cancer de Barretos, Barretos, São Paulo, BRA
5University of São Paulo, Department of Hematology, Hemotherapy & Cell Therapy, University of São Paulo, São Paulo, São Paulo, Brazil
6CEPHO FMABC (Centro de Estudos e Pesquisa em Hematologia e Oncologia)/ Hospital Estadual Mario Covas - Faculdade de Medicina do ABC, Santo Andre, Brazil
7University of Campinas, São Paulo, BRA
8Santa Casa de São Paulo Medical School, Sao Paulo, Brazil
9Beneficencia Portuguesa Hospital, Sao Paulo, Brazil
10HemoMed, Sao Paulo, Brazil
11Ophir Loyola Hospital, Belém, Brazil
12Federal University of Sao Paulo, Sao Paulo, Brazil
13HUCFF / UFRJ, Rio de Janeiro, Brazil
14Federal University of Paraná, Parana, Brazil
15Luxemburgo Hospital, Belo Horizonte, Brazil
16State of Rio de Janeiro University, Rio De Janeiro, Brazil
17Federal University of Ceara, Fortaleza, Brazil
18CEPON, Florianopolia, Brazil
19CECAN, Natal, Brazil
20Hematology and Oncology Clinics, Cancer Hospital of Cascavel – UOPECCAN, Cascavel, Brazil
21Santa Marcelina Hospital, São Paulo, AL, BRA
22Amor Amazônia Hospital, Porto Velho, Brazil
23Albert Einstein Israelite Hospital, Sao Paulo, Brazil
24Hospital do Servidor Público do Estado de São Paulo – IAMSPE. São Paulo – Brazil, Sao Paulo, Brazil
25Ribeirao Preto Medical School - University of Sao Paulo, Ribeirao Preto, Brazil
26Hospital Beneficencia Portuguesa de SP, Sao Paulo, Brazil
27Prevent Senior, SAO PAULO, Brazil
28Federal da Bahia Hospital, Salvador, Brazil
29Hospital Das Clínicas UNESP, Botucatu, Brazil
30Cancer National Institute- INCA, Rio de Janeiro, Brazil
31Campos Medical School, Rio da Janeiro, Brazil
32Santa Lucia Hospital, Brasilia, Brazil
33Aldenora Bello Hospital, Sao Luis, Brazil
34Samaritano Hospital – Higienopolis, São Paulo, Brazil
35Paulistano Hospital, Sao Paulo, Brazil
36Santa Casa de Belo Horizonte, Belo Horizonte, Brazil
37Juiz De Fora Federal University, Juiz de Fora, Brazil
38Federal University of Goias, Goiania, Brazil
39University of Modena and Reggio Emilia, Modena, Italy
40University of Campinas, São Paulo, Brazil
41Santa Casa Medical School, Sao Paolo, Brazil
42Samaritano Hospital, Sao Paulo, Brazil

Introduction: T cell lymphomas (NHL-T) account for 10-15% of all non-Hodgkin lymphomas (NHL). They are a heterogeneous group of infrequent neoplasms with a variable clinical course but prevalently aggressive behavior and high mortality rates. Diagnosis is still challenging and there has been little change in the overall prognosis over the last two decades. In spite of IPI (International Prognostic Index) that include extranodal (EN) site in its variables, lack is known regarding EN involvement in nodal peripheral T cell lymphomas- PTCL (PTCL-NOS, TFH and ALCL ALK+/ALK-) location or impact on prognosis).

Objective: We aim to evaluate number of extranodal (EN) sites in nodal PTCL lymphomas (PTCL-NOS, TFH and ALCL ALK+/ALK-) and its specific location as a surrogate for overall survival (OS) and progression free survival (PFS). Also generate hypothesis for further molecular analysis.

Methodology: Brazil T-cell project is a national, ambispective study of patients with histological diagnosis of PTCL diagnosed from January 2015 to December 2022. Approval for the study was obtained at the coordinating center (Samaritano Hospital – São Paulo) and at each participating center as per the institutional standard before initiation. Those selected for the study were previously untreated patients age ≥ 19 years, with de novo PTCL or natural killer/T-cell lymphoma. At each institution, the local pathologist reviewed the diagnose. Clinical information included coded patient and site identifiers, sex, date of birth, date and site of diagnostic biopsy, sites of disease, EN (location and number), methodology of staging (clinical, CT or Pet) and Ann Arbor stage. Initial therapy and response; details of remission, progression, or relapse; and subsequent therapies, along with survival status and cause of death. Treatment outcome was determined by OS and PFS. REDcap Platform (by Vanderbilt) has been used to collect and store data and for descriptive analysis the IBM-SPSS version 24 was applied. Kaplan-Meier method estimated the OS, whereas Log-Rank tests to compare its curves. This trial is registered at Clinical trials (NCT03207789).

Results: Of 621 registered we selected 198 patients (pts) diagnosed with nodal PTCL with at least one EN involvement [Cohort 1 EN involvement equal to one (148 pts) and Cohort 2 EN involvement ³ 2 (50 patients)]. Considering all 198 pts (Cohort 1 and 2) there was a slight male predominance (63%); median age 53 years; 79% were staged III or IV; 81.5 were IPI 2 or more. Most frequently histology was PTCL-NOS (46%), followed by ALCL ALK+ (32%), ALCL ALK- (12.5%) and TFH (9.5%). The majority had B Symptoms (63%); 37.5% had Bone Marrow infiltration. The chemotherapy most frequently chosen were CHOEP (54.5%) followed by CHOP (19.5%). Transplant was used as consolidation in 20% of the cases. Almost half of patients achieved complete response after first line (44%), although 38% relapsed. Cohort 1 (EN=1) and 2 (EN ³ 2) were similar regarding clinical characteristics, except, for stage III-IV (73% vs 96%; p <.0001); IPI ³ 3 (37.5% vs. 82%; p <.0001) and ECOG (22 vs. 48%; p=.001), respectively. Therefore, translating in a more advanced disease in Cohort 2. The most common extranodal location in Cohort 1 (EN=1) was Skin/ Subcutaneous (35%), followed by gastrointestinal tract (18%) and lung (16%). NHL-T subtypes behaved similarly in this EN exploratory analysis, with a better OS and PFS in ALCL ALK+, followed by ALK- and PTCL-NOS. There was no difference in PFS in Cohort 1 (EN=1) and 2 (EN ³ 2), but there was a slight difference in Overall survival (55% vs. 42% in 12 months; p=0.06), suggesting EN sites involvement assessed by CT and PET-CT as possible surrogate for outcomes in this population.

Conclusion: NHL-T is still unmet medical need considering suboptimal outcome in treatment and survival. New biological and clinical finding are still necessary to adequate stratify this group of patients, considering poor performance of IPI and PIT scores. Number and location of EN sites involvement may be a possible surrogate for outcome, which can be a reflect of a distinct biology, that needs further investigation. Registries are of importance considering rarity and poor prognosis of this diseases and an adequate instrument to hypothesis generation.

Disclosures: Cle: Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria, Patents & Royalties; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eli Lilly: Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Membership on an entity's Board of Directors or advisory committees; Pint Pharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gaiolla: Lilly, janssen, Abbvie, Takeda, MSD.: Speakers Bureau; Lilly, janssen, beigene, Abbvie, Roche: Honoraria; Janssen, Takeda: Other: Travel support. Perini: AstraZeneca, Janssen, MSD, Merck, Abbvie, Takeda: Consultancy; AstraZeneca, Janssen, MSD, Merck, Abbvie, Takeda: Speakers Bureau. Chiattone: ROCHE, ABBVIE, JANSSEN, AZ, LYLLI, TAKEDA: Honoraria; ROCHE, ABBVIE, JANSSEN, AZ, LYLLI, TAKEDA: Consultancy.

*signifies non-member of ASH